Bharat Biotech

Bharat Biotech International Limited is an Indian biotechnology company headquartered in Hyderabad and focused on drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals, and healthcare products. Its principal manufacturing operation is located in Genome Valley, Hyderabad, one of India's major life-sciences clusters. The company operates internationally and, according to the cited reference material, had more than 700 employees as of July 2020. The company has built its identity around vaccine research and production for infectious diseases affecting both Indian and international populations. Its portfolio includes vaccines associated with Japanese encephalitis, influenza A(H1N1), rabies, and other viral and bacterial diseases. Bharat Biotech has also worked on vaccines for emerging infections, including chikungunya and Zika, and maintains biosafety level 3 laboratory capabilities for work requiring enhanced containment. One of its best-known achievements is ROTAVAC, a recombinant and naturally attenuated rotavirus vaccine developed to address severe diarrhoeal disease. The company has also developed a tetanus-toxoid conjugated typhoid vaccine, described in the reference material as the first vaccine of its type. These products reflect Bharat Biotech's emphasis on vaccine platforms intended for large-scale public-health use, including products designed for diseases that impose a substantial burden in lower- and middle-income countries. Bharat Biotech became especially prominent during the COVID-19 pandemic through the development of Covaxin, an inactivated-virus COVID-19 vaccine developed with support from India's National Institute of Virology and the Indian Council of Medical Research. The company received Indian regulatory permission in June 2020 to conduct Phase I and Phase II clinical trials, with trial sites selected by the Indian Council of Medical Research. Covaxin later became a major part of India's domestic COVID-19 vaccination response and was authorized for use in children aged two to eighteen in October 2021, according to the reference material. The company has also pursued intranasal COVID-19 vaccine research. In 2020 it announced work on BBV154, a single-dose intranasal candidate developed with Precision Virologics and Washington University School of Medicine in St. Louis. Separately, Bharat Biotech partnered with FluGen and the University of Wisconsin-Madison in April 2020 on COVID-19 vaccine development. As of May 2025, the reference material states that Bharat Biotech had delivered more than nine billion vaccine doses globally, held more than 145 global patents, maintained a portfolio of more than 19 vaccines and four biotherapeutics, and had registrations in more than 125 countries. The company is therefore positioned as an export-oriented Indian vaccine manufacturer with capabilities spanning discovery, clinical development, regulatory registration, and industrial production. Its current profile combines established immunization products with continued research into emerging pathogens and next-generation delivery methods, including oral and intranasal vaccines.

Bharat Biotech International Limited is an Indian biotechnology company based in Hyderabad. Its activities cover the full vaccine and biopharmaceutical development chain, including discovery, development, manufacturing, and international registration. The company's main manufacturing facility is situated in Genome Valley, Hyderabad, and its laboratory infrastructure includes biosafety level 3 facilities. The company developed a business and scientific profile centered on vaccines for infectious diseases. Its portfolio has included products associated with Japanese encephalitis, influenza A(H1N1), rabies, rotavirus, typhoid, and other viral or bacterial diseases. Bharat Biotech's work on rotavirus led to ROTAVAC, described in the reference material as an eco-friendly recombinant and naturally attenuated vaccine. The company also developed a tetanus-toxoid conjugated typhoid vaccine, identified as the first vaccine of its kind. These programs placed the company within India's expanding vaccine and biotechnology sector while also giving it an international public-health orientation. Bharat Biotech has pursued research into diseases that have historically affected populations in developing countries as well as diseases that can produce global outbreaks. The reference material identifies the company as one of the early developers of vaccines for chikungunya and Zika. Its activities extend beyond conventional vaccine products to biotherapeutics, pharmaceuticals, and other healthcare products. The COVID-19 pandemic marked a major turning point in the company's public profile. In April 2020, Bharat Biotech announced a collaboration with FluGen and the University of Wisconsin-Madison to explore a COVID-19 vaccine. In May of that year, India's National Institute of Virology, under the Indian Council of Medical Research, approved and supplied virus strains for development of an indigenous vaccine. On June 29, 2020, India's Drugs Controller General authorized Phase I and Phase II clinical trials for Covaxin. The trial program used randomized, double-blind, placebo-controlled studies at twelve sites selected by the Indian Council of Medical Research, and the Central Drug Laboratory in Kasauli was involved in testing experimental batches. Bharat Biotech also announced a separate intranasal COVID-19 program in September 2020. Codenamed BBV154, the candidate was described as a single-dose intranasal vaccine being developed with Precision Virologics and Washington University School of Medicine in St. Louis. Covaxin subsequently received approval for use in children aged two to eighteen on October 12, 2021, according to the cited material. The company attracted adverse attention in March 2021 when Reuters reported that Red Apollo, characterized as a Chinese state-backed cyber-espionage group, had targeted Bharat Biotech's intellectual property for exfiltration. The report illustrates the strategic value of vaccine research and manufacturing knowledge during the pandemic, but the supplied material does not establish that confidential information was successfully stolen. By May 2025, Bharat Biotech was reported to have delivered more than nine billion vaccine doses worldwide. It was also reported to hold more than 145 global patents, maintain a portfolio of over 19 vaccines and four biotherapeutics, and have product registrations in more than 125 countries. In the same period, the company completed Phase III clinical trials of Hillchol, an oral cholera vaccine showing efficacy against both Ogawa and Inaba serotypes. These developments reinforce Bharat Biotech's position as a research-led Indian vaccine producer with a substantial international manufacturing and distribution footprint.

1. 2025Hillchol Phase III trials completed

   The company completed Phase III clinical trials of its oral cholera vaccine Hillchol, reporting efficacy against the Ogawa and Inaba serotypes.

   Source
2. 2021Covaxin cleared for children aged two to eighteen

   Covaxin received approval for use in children between two and eighteen years of age.

   Source
3. 2020COVID-19 research partnerships announced

   Bharat Biotech announced collaborations with FluGen and the University of Wisconsin-Madison, and separately pursued an intranasal vaccine program with Precision Virologics and Washington University School of Medicine.

   Source
4. 2020Covaxin clinical development authorized in India

   India authorized Phase I and Phase II clinical trials for Covaxin, with twelve trial sites selected by the Indian Council of Medical Research.

   Source

An Indian, internationally oriented biotechnology and vaccine manufacturer combining infectious-disease research, clinical development, biosafety capabilities, and large-scale vaccine production. The brand is particularly associated with public-health immunization, products for diseases prevalent in emerging markets, and indigenous vaccine development.

• ROTAVACRotavirus vaccine

  ROTAVAC is Bharat Biotech's rotavirus vaccine, described in the reference material as an eco-friendly recombinant and naturally attenuated vaccine. It represents the company's work on preventing severe diarrhoeal disease and illustrates its focus on vaccines intended for broad public-health deployment.

• CovaxinCOVID-19 vaccine2020

  Covaxin is Bharat Biotech's indigenous COVID-19 vaccine developed with support from India's National Institute of Virology and the Indian Council of Medical Research. The candidate entered Indian Phase I and Phase II clinical trials in 2020 and was later approved for use in children aged two to eighteen.

• BBV154Intranasal COVID-19 vaccine candidate2020

  BBV154 is a single-dose intranasal COVID-19 vaccine candidate announced by Bharat Biotech in 2020. The program was developed with Precision Virologics and Washington University School of Medicine in St. Louis and was described as undergoing clinical trials in the supplied reference material.

• HillcholOral cholera vaccine

  Hillchol is Bharat Biotech's oral cholera vaccine. The reference material states that the company completed Phase III clinical trials in 2025 and demonstrated efficacy against both the Ogawa and Inaba serotypes.

• Typhoid conjugate vaccineTyphoid vaccine

  Bharat Biotech developed a tetanus-toxoid conjugated typhoid vaccine, described in the reference material as the world's first vaccine using that conjugation approach. The product reflects the company's focus on improving immunization options for bacterial diseases.

• 2020Proceed with Covaxin clinical developmentProduct launch

  During the COVID-19 pandemic, Bharat Biotech worked with India's National Institute of Virology and the Indian Council of Medical Research on an indigenous vaccine candidate.

  What changed. The company advanced Covaxin into Phase I and Phase II clinical trials after receiving authorization from India's Drugs Controller General.

  Aftermath. Covaxin became a prominent Bharat Biotech product and was later approved for children aged two to eighteen.

  Source
• 2020Develop an intranasal COVID-19 vaccine candidateProduct launch

  The pandemic created demand for vaccine delivery methods beyond conventional injections.

  What changed. Bharat Biotech announced manufacturing support for BBV154, a single-dose intranasal candidate developed with Precision Virologics and Washington University School of Medicine.

  Aftermath. The candidate entered clinical development, although the supplied material does not provide a final commercial outcome.

  Source

• 2025Hillchol completes Phase III clinical trials

  Bharat Biotech announced successful completion of Phase III clinical trials for its oral cholera vaccine Hillchol, with reported efficacy against both Ogawa and Inaba serotypes. The findings were published in the journal Vaccine.

  Product launchOther
  Source
• 2025Hillchol Phase III oral cholera vaccine trial completed

  Bharat Biotech reportedly completed Phase III clinical trials of Hillchol, an oral cholera vaccine candidate, with reported efficacy against the Ogawa and Inaba serotypes. The study findings were reported as published in the journal Vaccine.

  Product launchOther
  Source
• 2021Red Apollo reportedly targets Bharat Biotech intellectual property

  Reuters reported that Red Apollo, described as a Chinese state-backed cyber-espionage group, targeted Bharat Biotech's intellectual property for possible exfiltration.

  Other
  Source
• 2021Covaxin approved for children aged two to eighteen

  Bharat Biotech's Covaxin received approval for use in children between two and eighteen years of age, according to the cited reference material.

  RegulationProduct generation
  Source
• 2021Bharat Biotech targeted in reported cyber-espionage attempt

  Reuters reported that Red Apollo, described as a Chinese state-backed cyber-espionage group, targeted Bharat Biotech in an effort to obtain intellectual property. The supplied material characterizes this as an attempted data theft rather than a confirmed public disclosure of successfully exfiltrated proprietary information.

  Other
  Source
• 2021Covaxin receives authorization for children aged two to 18

  Reference material states that Covaxin was approved for use in children between two and 18 years of age on October 12, 2021.

  Regulation
  Source
• 2020Bharat Biotech partners on COVID-19 vaccine research

  Bharat Biotech announced a partnership with US-based FluGen and the University of Wisconsin-Madison to develop a COVID-19 vaccine.

  Product launchOther
  Source
• 2020India authorizes clinical trials for Covaxin

  India's drug regulator permitted Bharat Biotech to conduct Phase I and Phase II clinical trials of its indigenous COVID-19 vaccine candidate Covaxin. The Indian Council of Medical Research selected twelve trial sites, while the Central Drug Laboratory in Kasauli was involved in testing experimental batches.

  Product launchRegulation
  Source
• 2020Bharat Biotech announces intranasal COVID-19 vaccine candidate

  The company announced that it would manufacture BBV154, a single-dose intranasal COVID-19 vaccine candidate being developed with Precision Virologics and Washington University School of Medicine in St. Louis.

  Product launch
  Source

1. Bharat Biotech
2. 巴拉特生物技术成为据报道的网络间谍活动目标